Blog
John Warner Joins Zymergen To Accelerate Green Chemistry

John Warner Joins Zymergen To Accelerate Green Chemistry

Industry pioneer and world-renowned chemist John Warner has joined the Zymergen team as a Distinguished Research Fellow. John is a global leader in green chemistry, with hundreds of patents to his name, and a prominent academic figure who brought green chemistry to the mainstream.

The Bioeconomy Has Arrived

The Bioeconomy Has Arrived

The outbreak of COVID-19 is fueling an urgent need for discovery and development, particularly around medicine, testing and materials – all highly dependent on biology. Many private organizations and government agencies are working together, and teams of scientists across borders are breaking their culture of secrecy and competitive advantage to partner up, openly sharing data to solve major problems fast.

Advancing the Pace of New Material Discovery

Advancing the Pace of New Material Discovery

By merging enEvolv’s powerful platform technology with our existing genome engineering, automation and machine learning capabilities, we will dramatically improve our ability to discover, design and commercialize breakthrough biologically-manufactured products.

Welcome to Our New Board Members

Welcome to Our New Board Members

At Zymergen, we use biology to create never-before imagined materials. As we continue to scale and build our growing pipeline of next generation products, we’re proud to announce that we’ve appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to Zymergen’s Board of Directors. Jay will serve as Lead Independent Director.

AI in the Enterprise: Challenges and Opportunities (Part II: Challenges)

At Zymergen, we apply AI or machine learning techniques to many aspects of our high-throughput microbial genome assembly and testing systems and practices. Aaron Kimball, our CTO, offers his thoughts on what lessons we’ve learned as a result of this AI journey, and how these can be generalized to a broader business context.

AI in the Enterprise: Challenges and Opportunities (Part I: Opportunities)

At Zymergen, we apply AI or machine learning techniques to many aspects of our high-throughput microbial genome assembly and testing systems and practices. Aaron Kimball, our CTO, offers his thoughts on what lessons we’ve learned as a result of this AI journey, and how these can be generalized to a broader business context. In this two-part series, we will discuss first the opportunities and benefits brought to organizations by the use of AI.